Marina Coppola

Marina Coppola

Auto-generated profile, based on publicly available information

Marina Coppola

Veneto Institute of Oncology IOV IRCCS

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
Debora CarpaneseDebora Carpanese
Debora Carpanese
VRValentina Rossi
Valentina Rossi
VPVeronica Di Paolo
Veronica Di Paolo
LQLuigi Quintieri
Luigi Quintieri
APAlessandro Penna
Alessandro Penna
ARAntonio Rosato
Antonio Rosato
The two anti-epidermal growth factor receptor monoclonal antibodies (mAbs) cetuximab and panitumumab are the pillars for the treatment of EGFR-positive, KRAS wild-type metastatic colorectal cancers. However, stability data of these mAbs are generally missing or incomplete. Here, we report for the first time an orthogonal analysis of the stability of cetuximab (Erbitux®) and panitumumab (Vectibix®), either undiluted vial leftovers or saline dilutions in polyolefin/polyamide infusion bags. All samples were stored at 2-8°C protected from light, according to their summary of product characteristics (SmPCs). Alternatively, opened vials and preparations were maintained at 25°C for 15 h, and then stored again at 2-8°C protected from light to mimic a temporary interruption of the cold chain. Vial leftovers proved stable up to 180 days when stored according to their SmPCs, while compounded preparations in infusion bags maintained their physiochemical, biological and microbiological stability up to 30 days. Additionally, no changes were detected up to 30 days for the same samples undergoing a thermal excursion. Our results provide additional rationale to the SmPCs, crucial especially in the case of reassignment and pre-preparation of bags. This information will allow hospitals to achieve significant cost savings, and better organization of the entire therapeutic process.

1 January 2021 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Open access
MMMario Malzoni
Mario Malzoni
MCMarina Coppola
Marina Coppola
MRMarianna Rasile
Marianna Rasile
DLDomenico Luzzolino
Domenico Luzzolino
LCLucia Casarella
Lucia Casarella
FFFrancesca Falcone
Francesca Falcone
To show the surgical steps used to perform rectal disc excision in a context of deep infiltrating endometriosis characterized by contiguity between intestinal lesion and retrocervical region. Step-by-step video demonstration of the technique. Although surgical options for the management of rectosigmoid endometriosis have increasingly been investigated, there is no consensus regarding patient eligibility for shaving, discoid or segmental resection. In our practice, candidates for rectosigmoid disc excision are considered women with nodules large ≤3 cm and deep >7 mm [1]. Such a patients' selection, together with the adoption of a standardized surgical technique, has allowed us to maximize the chance of successful discoid resection, minimizing the complications potentially derivable from this surgical procedure. The patient was a 30-year-old woman with a history of constipation, dyschezia, dysmenorrhea, dyspareunia and chronic pelvic pain unresponsive to hormonal therapies. Preoperative ultrasonography showed complete obliteration of the Douglas' pouch due to a rectal endometriotic nodule (21 × 7 × 12 mm) in contiguity with a deeply infiltrating retrocervical lesion (28 × 10 × 27 mm). The rectal nodule resulted to infiltrate the tunica muscularis with a distance from the anal verge of 9 cm and an estimated stenosis of 35%. A 3-dimensional laparoscopy was performed. After rectal mobilization and rectovaginal space opening, the intestinal nodule was isolated in its entire circumference. A 33 mm transanal circular stapler was inserted into the rectum via the anus and used to perform disc excision and suture of the rectal wall. The overall operative time was 55 minutes. No intraoperative complication occurred. Complete excision of endometriosis was achieved. The estimated blood loss was 10 mL. Intra-abdominal drain was not placed and urinary catheter was removed at the end of surgery. The patient was discharged 3 days after surgery and did not experience post-operative complications. Diameters of bowel endometriotic nodule, measuring on fresh specimen, were 20 × 7 × 13 mm. Advanced laparoscopic surgical skills are needed to perform an effective and safe rectal discoid resection. Sub-specialization and an adequate pre-operative evaluation are of utmost importance to appropriately plan the treatment strategy against bowel endometriosis.

1 January 2025 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
ARAlberto Russi
Alberto Russi
CSCamilla Saran
Camilla Saran
GZGiulia Zanchetta
Giulia Zanchetta
GZGiorgia Zorzetto
Giorgia Zorzetto
GCGiovanna Crivellaro
Giovanna Crivellaro
MCMarina Coppola
Marina Coppola
Purpose: Inappropriate use of antibiotics contributes to the increase in antimicrobial resistance with negative health safety implications. Global health organizations have promoted projects to improve proper and rational use of antibiotics. Recent studies show how antibiotics can also influence the efficacy of immune checkpoint inhibitors (ICIs) treatment in cancer patients. This work analyzes the impact of concomitant antibiotic therapy in patients affected by skin, lung, and kidney cancer, who started immunotherapy in 2020‐2021 at Veneto Institute of Oncology IRCCS. The aim of this study is to evaluate clinical outcomes, treatment efficacy, discontinuation causes, and occurrence of adverse drug reactions in cancer patients treated with ICIs. Methods: Data from the real‐world retrospective study were extracted from Territorial Pharmaceutical Care databases, medical records, and the AIFA registry. A descriptive analysis of the study population was performed, as well as of patient outcomes in terms of progression‐free survival (PFS) and overall survival (OS). Results: A total of 239 subjects affected by kidney (8%), lung (48%), and skin (44%) cancer were enrolled; of these, 50%, 32%, 9%, and 9% were treated with single‐agent nivolumab, pembrolizumab, atezolizumab, and cemiplimab, respectively. A total of 119 patients received concomitant antibiotic therapy. Median OS was 8.8 months (95% CI: 5.02–11.8) and 31.05 months (95% CI: 24.81–NA) in subjects with high and low antibiotic exposure, respectively. Multivariate subgroup analysis confirmed that high antibiotic exposure is an unfavorable factor also for median PFS. Conclusion: A prolonged exposure to antibiotics correlates with unfavorable outcomes in cancer patients undergoing concomitant immunotherapy. Thus, managing antibiotic exposure is fundamental for optimizing ICI treatment.

6 November 2025 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Open access
GFGianpaolo Franzoso
Gianpaolo Franzoso
GZGiorgia Zorzetto
Giorgia Zorzetto
SBSusy Dal Bello
Susy Dal Bello
AGAlessandro Giuriola
Alessandro Giuriola
ACAgnese Casarin
Agnese Casarin
MCMarina Coppola
Marina Coppola
Cystoscopy is a high-frequency endoscopic procedure in both oncologic and non-oncologic urology. Healthcare systems are increasingly required to adopt evidence-based and sustainable strategies for device management. This institutional cost-opportunity analysis compared disposable and reusable cystoscope devices in a high-volume oncology center. Retrospective real-world data on disposable use were combined with theoretical modeling for reusable systems under three operational scenarios: disposable, reusable with standard sterilization, and reusable with urgent sterilization, each analyzed in optimized and maximal-cost conditions. Disposable cystoscopes cost €188,75.00 per procedure, halved procedural time (15 vs. 30 minutes), and ensured workflow continuity. Reusable systems were economically sustainable only under optimized reprocessing (two cystoscopes per cycle, €180,88.00 per procedure). Under urgent or single-scope sterilization, per-procedure costs increased to €198,88.00 with annual excesses of up to €79,820.88 compared to disposable systems. Disposable devices minimized downtime and logistical complexity, particularly in high-demand settings. Reusable cystoscopes achieve economic sustainability only when supported by standardized, high-efficiency workflows, while disposables provide flexibility and reliability in routine and urgent care. Despite its single-center, retrospective design, this framework provides transferable insights for healthcare institutions aiming to align cost management, service quality, and sustainability in cystoscopic practice. Future multicentric studies are warranted to validate these findings across diverse organizational settings.